Detalles de la búsqueda
1.
Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.
Antimicrob Agents Chemother
; 65(12): e0121621, 2021 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34570651
2.
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.
Clin Infect Dis
; 68(4): 535-544, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30184165
3.
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Lancet HIV
; 11(2): e75-e85, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38141637
4.
Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients.
Antimicrob Agents Chemother
; 56(6): 3101-6, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22430964
5.
Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK.
HIV Clin Trials
; 13(4): 228-32, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22849964
6.
High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial.
J Infect Dis
; 203(6): 756-64, 2011 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21325137
7.
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Clin Infect Dis
; 53(8): 807-16, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21921224
8.
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Lancet
; 375(9712): 396-407, 2010 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-20074791
9.
Changes in weight and BMI with first-line doravirine-based therapy.
AIDS
; 35(1): 91-99, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33048879
10.
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.
Lancet HIV
; 8(6): e324-e333, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34000227
11.
Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.
J Acquir Immune Defic Syndr
; 87(2): 801-805, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33633036
12.
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Lancet
; 374(9692): 796-806, 2009 Sep 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-19647866
13.
Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development.
J Acquir Immune Defic Syndr
; 85(5): 635-642, 2020 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32925358
14.
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Lancet HIV
; 7(1): e16-e26, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31740348
15.
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
J Acquir Immune Defic Syndr
; 81(4): 463-472, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30985556
16.
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Lancet HIV
; 5(5): e211-e220, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29592840
17.
Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies.
Open Forum Infect Dis
; 4(1): ofw047, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28480227
18.
Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.
Neurology
; 88(23): 2198-2206, 2017 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28490648
19.
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
Lancet HIV
; 4(11): e486-e494, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28918877
20.
Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned.
JAMA Neurol
; 72(12): 1491-500, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26523919